Biomarkers

Molecular genetics company Mainz Biomed has enrolled its first patient in an international clinical study assessing the potential combination of gene expression (mRNA) biomarkers with a diagnostic test for colorectal cancer.  The ColoFuture clinical study will see Mainz Biomed integrate a portfolio of novel gene expression (mRNA) biomarkers into its ColoAlert detection test for colorectal […]

Suchita Gupta examines the immunochemistry reagents market post Covid-19. Immunohistochemistry (IHC) is referred to as the study of a branch of chemistry including the study of various components and functions of the immune system with the application of antigen & antibodies as chemical reagents. It is a technique that combines anatomy, physiology, immunology and biochemistry.  […]

PreOmics has raised €13.5 million in a Series B financing round provided by Bruker Corporation, which is expected to broaden the market opportunities for both PreOmics’ platform technologies and Bruker’s  proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for CRO and biopharmaceutical companies.  Dr. Garwin […]

This On Demand webinar by Olink features Bill Hunt, Director of Product Management at Fluidigm, and Dr Jenny Rubin, Development Engineer at Olink Proteomics. The webinar examines the new Olink Signature Q100, a benchtop system for protein biomarker analysis.  Hunt discusses “Signature Q100 System – Evolution of workhorse for protein expression”, while Rubin will look at the “Side by side comparison of Olink to […]

Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia.  Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over the last decade. One of the recognised limitations of previous […]

Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).   Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO 500) content, enabling genomic profiling assays in a […]

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven.  In the US study, which had included […]

In the UK, a University of Manchester-led team of scientists has discovered that the most common form of adult blindness is probably caused by a failure of at least one of five proteins to regulate the immune system. The breakthrough could one day herald the development of transformative treatments for developing age-related macular degeneration (AMD), […]

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel drug development strategy, leveraging digital […]

Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with Dr Paul Wylie, Director of Multiplex […]